Growth inhibition by glucocorticoid treatment in salt wasting 21-hydroxylase deficiency: In early infancy and (pre)puberty

Journal of Clinical Endocrinology and Metabolism

Volumn 88, Issue 8, 2003, Pages 3525-3530

  Stikkelbroeck, Nike M M L ^a   Van't Hof Grootenboer, Bep A E ^a   Hermus, Ad R M M ^a   Otten, Barto J ^a   Van't Hof, Martin A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; GLUCOCORTICOID; HYDROCORTISONE; MINERALOCORTICOID; STEROID 21 MONOOXYGENASE;

ADOLESCENT; AGE DISTRIBUTION; ARTICLE; BODY HEIGHT; BODY WEIGHT; CHILD; CLINICAL ARTICLE; CONGENITAL ADRENAL HYPERPLASIA; CONTROLLED STUDY; CORRELATION ANALYSIS; COVARIANCE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; FEMALE; GROWTH INHIBITION; GROWTH REGULATION; HEIGHT FOR AGE Z SCORE; HUMAN; INFANT; INFANT DISEASE; MALE; PREPUBERTY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SALT LOSING NEPHRITIS; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; STEROID THERAPY; VIRILIZATION; WEIGHT FOR AGE Z SCORE; WEIGHT FOR HEIGHT Z SCORE;

ADOLESCENT; ADRENAL HYPERPLASIA, CONGENITAL; AGING; ANALYSIS OF VARIANCE; BODY HEIGHT; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCOCORTICOIDS; GROWTH DISORDERS; HUMANS; INFANT; LONGITUDINAL STUDIES; MALE; RETROSPECTIVE STUDIES; STEROID 21-HYDROXYLASE;

EID: 0042885738     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2002-030011     Document Type: Article

References (29)

1. Muirhead S, Sellers EA, Guyda H 2002 Indicators of adult height outcome in classical 21-hydroxylase deficiency congenital adrenal hyperplasia. J Pediatr 141:247-252
2. Van der Kamp HJ, Otten BJ, Buitenweg N, Muinck Keizer-Schrama SMPF, Oostdijk W, Jansen M, Delemarre-de-Waal HA 2002 Longitudinal analysis of growth and puberty in 21-hydroxylase deficiency patients. Arch Dis Child 87:139-144
3. Jaaskelainen J, Voutilainen R 1997 Growth of patients with 21-hydroxylase deficiency: an analysis of the factors influencing adult height. Pediatr Res 41:30-33
4. Hargitai G, Solyom J, Battelino T, Lebl J, Pribilincova Z, Hauspie R, Kovacs J, Waldhauser F, Frisch H 2001 Growth patterns and final height in congenital adrenal hyperplasia due to classical 21-hydroxylase deficiency: results of a multicenter study. Horm Res 55:161-171
5. Manoli I, Kanaka-Gantenbein C, Voutetakis A, Maniati-Christidi M, Dacou-Voutetakis C 2002 Early growth, pubertal development, body mass index and final height of patients with congenital adrenal hyperplasia: factors influencing the outcome. Clin Endocrinol (Oxf) 57:669-676
6. Eugster EA, Dimeglio LA, Wright JC, Freidenberg GR, Seshadri R, Pescovitz OH 2001 Height outcome in congenital adrenal hyperplasia caused by 21-hydroxylase deficiency: a meta-analysis. J Pediatr 138:26-32
7. Kirkland RT, Keenan BS, Holcombe JH, Kirkland JL, Clayton GW 1978 The effect of therapy on mature height in congenital adrenal hyperplasia. J Clin Endocrinol Metab 47:1320-1324
8. Girgis R, Winter JSD 1997 The effects of glucocorticoid replacement therapy on growth, bone mineral density, and bone turnover markers in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 82:3926-3929
9. Hochberg Z 2002 Mechanisms of steroid impairment of growth. Horm Res 58(Suppl 1):33-38
10. Cameron FJ, Kaymakci B, Byrt EA, Ebeling PR, Warne GL, Wark JD 1995 Bone mineral density and body composition in congenital adrenal hyperplasia. J Clin Endocrinol Metab 80:2238-2243
11. Silva IN, Kater CE, Cunha CF, Viana MB 1997 Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia. Arch Dis Child 77:214-218
12. Brook CG, Zachmann M, Prader A, Murset G 1974 Experience with long-term therapy in congenital adrenal hyperplasia. J Pediatr 85:12-19
13. Fredriks AM, van Buuren S, Burgmeijer RJ, Meulmeester JF, Beuker RJ, Brugman E, Roede MJ, Verloove-Vanhorick SP, Wit JM 2000 Continuing positive secular growth change in The Netherlands 1955-1997. Pediatr Res 47:316-323
14. Miller WL 1994 Clinical review 54: genetics, diagnosis, and management of 21-hydroxylase deficiency. J Clin Endocrinol Metab 78:241-246
15. Bailey BJ, Briars GL 1996 Estimating the surface area of the human body. Stat Med 15:1325-1332
16. De Wijn J, De Haas J 1960 Growth diagrams for ages 1-25 years in The Netherlands. Leiden: Wolters-Noordhoff; 1-29
17. Van Wieringen J, Wafelbakker F, Verbrugge H, De Haas J 1971 Growth diagrams 1965 Netherlands. Leiden/Groningen: Wolters-Noordhoff; 1-69
18. Roede M, Van Wieringen J 1985 Growth diagrams 1980: Netherlands third nation-wide survey. Tijdschr Soc Gezondheidsz 63(Suppl):1-34
19. van't Hof MA, Haschke F 2000 Euro-Growth references for body mass index and weight for length. Euro-Growth Study Group. J Pediatr Gastroenterol Nutr 31(Suppl 1):S48-S59
20. Senn S 1997 Statistical issues in drug development. Chichester: Wiley & Sons
21. Tanner J, Whitehouse R, Takaishi M 1966 Standards from birth to maturity for height, weight, height velocity and weight velocity: British children, 1965 part II. Arch Dis Child 41:613-635
22. Ghali I, David M, David L 1977 Linear growth and pubertal development in treated congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Clin Endocrinol (Oxf) 6:425-436
23. Rasat R, Espiner EA, Abbott GD 1995 Growth patterns and outcomes in congenital adrenal hyperplasia; effect of chronic treatment regimens. N Z Med J 108:311-314
24. Thilen A, Woods KA, Perry LA, Savage MO, Wedell A, Ritzen EM 1995 Early growth is not increased in untreated moderately severe 21-hydroxylase deficiency. Acta Paediatr 84:894-898
25. Hauffa BP, Winter A, Stolecke H 1997 Treatment and disease effects on short-term growth and adult height in children and adolescents with 21-hydroxylase deficiency. Klin Padiatr 209:71-77
26. Clayton P, Gill M 2001 Normal growth and its endocrine control. In: Brook CGD, Hindmarsh PC, eds. Clinical pediatric endocrinology, 4th Ed. London: Blackwell; 95-114
27. Yu AC, Grant DB 1995 Adult height in women with early-treated congenital adrenal hyperplasia (21-hydroxylase type): relation to body mass index in earlier childhood. Acta Paediatr 84:899-903
28. Jaaskelainen J, Voutilainen R 1996 Bone mineral density in relation to glucocorticoid substitution therapy in adult patients with 21-hydroxylase deficiency. Clin Endocrinol (Oxf) 45:707-713
29. Knorr D, Hinrichsen-de-Lienau SG 1988 Persistent obesity and short final height after corticoid overtreatment for congenital adrenal hyperplasia (CAH) in infancy. Acta Paediatr Jpn 30(Suppl):89-92